The entry of biosimilar medicines into the Spanish market, after the loss of patent for reference biological medicines, has meant a before and after in pharmaceutical provision.

The determined commitment of pharmaceutical companies to these medicines has contributed to improving the sustainability of the National Health System while expanding and streamlining patient access to biological therapies.

The use of biosimilars by healthcare professionals has been gradually increasing since the appearance of the first biosimilar medicine in 2006.

This section presents graphically the data on the current situation of biosimilars in Spain and its evolution over time, from the most general data* to the most detailed.

*Data source: Ministry of Health of Spain. The data is presented in packaging.